FDA approves test to identify patients eligible for treatment with Zejula in late-line Ovarian Cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved myChoice CDx for use as a companion diagnostic to identify women with advanced ovarian cancer who are candidates for Zejula (niraparib) in the late-line treatment setting.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login